These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32108029)

  • 1. A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2).
    Freedland SJ; Allen J; Jarman A; Oyekunle T; Armstrong AJ; Moul JW; Sandler HM; Posadas E; Levin D; Wiggins E; Howard LE; Wu Y; Lin PH
    Clin Cancer Res; 2020 Jun; 26(12):3035-3043. PubMed ID: 32108029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum metabolomic analysis of men on a low-carbohydrate diet for biochemically recurrent prostate cancer reveals the potential role of ketogenesis to slow tumor growth: a secondary analysis of the CAPS2 diet trial.
    Chi JT; Lin PH; Tolstikov V; Howard L; Chen EY; Bussberg V; Greenwood B; Narain NR; Kiebish MA; Freedland SJ
    Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):770-777. PubMed ID: 35338353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight loss via a low-carbohydrate diet improved the intestinal permeability marker, zonulin, in prostate cancer patients.
    Lin PH; Howard L; Freedland SJ
    Ann Med; 2022 Dec; 54(1):1221-1225. PubMed ID: 35486445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.
    Freedland SJ; Howard L; Allen J; Smith J; Stout J; Aronson W; Inman BA; Armstrong AJ; George D; Westman E; Lin PH
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):428-437. PubMed ID: 30664736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low Carbohydrate Diets and Estimated Cardiovascular and Metabolic Syndrome Risk in Prostate Cancer.
    Freedland SJ; Howard LE; Ngo A; Ramirez-Torres A; Csizmadi I; Cheng S; Mack A; Lin PH
    J Urol; 2021 Dec; 206(6):1411-1419. PubMed ID: 34259565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
    O'Brien MF; Cronin AM; Fearn PA; Smith B; Stasi J; Guillonneau B; Scardino PT; Eastham JA; Vickers AJ; Lilja H
    J Clin Oncol; 2009 Aug; 27(22):3591-7. PubMed ID: 19506163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
    Liu C; Zhu Y; Su H; Xu X; Zhang Y; Ye D; Hu S
    Prostate; 2018 Dec; 78(16):1215-1221. PubMed ID: 30027591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
    Howard LE; Moreira DM; De Hoedt A; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
    BJU Int; 2017 Nov; 120(5B):E80-E86. PubMed ID: 28371163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group.
    Teeter AE; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2009 Dec; 104(11):1604-9. PubMed ID: 19549124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a 2-year home-based endurance training intervention on physiological function and PSA doubling time in prostate cancer patients.
    Hvid T; Lindegaard B; Winding K; Iversen P; Brasso K; Solomon TP; Pedersen BK; Hojman P
    Cancer Causes Control; 2016 Feb; 27(2):165-74. PubMed ID: 26573844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
    Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality.
    Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Dorey FJ; Walsh PC; Partin AW
    J Clin Oncol; 2007 May; 25(13):1765-71. PubMed ID: 17470867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Greatest Percentage Involved Core Length and Risk of Clinically Significant Prostate-Specific Antigen Failure After Radical Prostatectomy.
    Cheney MD; Zhang D; Chen MH; Loffredo MJ; Richie JP; D'Amico AV
    Clin Genitourin Cancer; 2015 Aug; 13(4):338-343. PubMed ID: 25862320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression.
    Lohm G; Neumann K; Budach V; Wiegel T; Hoecht S; Gollrad J
    Strahlenther Onkol; 2018 Apr; 194(4):325-332. PubMed ID: 29255924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer.
    Pantuck AJ; Pettaway CA; Dreicer R; Corman J; Katz A; Ho A; Aronson W; Clark W; Simmons G; Heber D
    Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):242-8. PubMed ID: 26169045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markers and meaning of primary treatment failure.
    Swindle PW; Kattan MW; Scardino PT
    Urol Clin North Am; 2003 May; 30(2):377-401. PubMed ID: 12735513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a 6-month, low-carbohydrate diet on glycaemic control, body composition, and cardiovascular risk factors in patients with type 2 diabetes: An open-label randomized controlled trial.
    Gram-Kampmann EM; Hansen CD; Hugger MB; Jensen JM; Brønd JC; Hermann AP; Krag A; Olsen MH; Beck-Nielsen H; Højlund K
    Diabetes Obes Metab; 2022 Apr; 24(4):693-703. PubMed ID: 34984805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
    Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
    J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial of 130 g/day low-carbohydrate diet in type 2 diabetes with poor glycemic control.
    Sato J; Kanazawa A; Makita S; Hatae C; Komiya K; Shimizu T; Ikeda F; Tamura Y; Ogihara T; Mita T; Goto H; Uchida T; Miyatsuka T; Takeno K; Shimada S; Ohmura C; Watanabe T; Kobayashi K; Miura Y; Iwaoka M; Hirashima N; Fujitani Y; Watada H
    Clin Nutr; 2017 Aug; 36(4):992-1000. PubMed ID: 27472929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.